“The medical device segment has been the driver of the group’s growth over the last three years, a situation Shiue does not see changing anytime soon.. Based on the products that we are jointly developing with our clients, we can comfortably say that we see growth and visibility over the next 10 years,” he adds.
From the article in the Edge, there seems to be long term growth in this company. I wonder how big can Scomnet grow?
Year 2019 before covid : "Scomnet successfully placed a deal with Edwards Lifesciences Corp and Denmark-based Ambu as its two main customers, for 10 years"
Year 2020 during covid : A surge of catheter demand for covid usage by US hospital, this is not included others medical equipment manufactured by scomnet which direct/indirectly for covid usage. The arrival of Covid 19 undeniably/unexpectedly increase the revenue for Scomnet.
Just based on this two scenarios you may figure it out how Scomnet will perform this year, and i'm yet to stated out the calculated fair value which over the current share price for scomnet.
hi everyone. i think it's important to note that Scomnet did not only produce a successful product for Covid treatment. Their core business is also in electrical and electronic cables; an industry that is poised to prosper. Nevertheless their disposable medical consumables will be the main driver this year for their huge growth and earnings.
With a stronger business volume from existing and new clients, we are confident that SMP will help the Group sail out of troubled waters. In addition, with several new products in the pipeline for 2020, this will provide further boost to the Group’s financial performance. Overall, we expect SMP’s revenue to increase by 30% to 40% in FY2020
Supercomal Medical Products Sdn Bhd (“SMP”), we are confident to sail through any arising challenges on the back of higher new product orders. In addition, given that SMP is a key supplier to two of the world’s leading medical device makers as elaborated below, we are sanguine of the Group’s prospects in FY2020 amid current market challenges.It should be noted that several key products of SMP are utilised in critical medical devices that are needed in the treatment of COVID-19 patients. Among the critical medical devices are disposable bronchoscopes, which are used in the first line of lung treatment for patients with suspected or confirmed COVID-19 infections, and the critical care monitoring cable that is presently being used for COVID-19 patients in the Intensive Care Unit.
The ar is out. Looks like the Co is doing well. According to the ar the revenue is expected to increase 30 to 40 %. I take 2019 profit of 18.8 m n average it to 4.7m per quarter. Then assuming the profit growth of 30% then the estimated profit for the first quarter will be around 6.1m. And compare it to the preceding quarter of 3.7 it means an increase of 65%.The market will receive this increase with strong fervour. I hope. Any comments?
We are pleased to announce that several new products of SMP have come to the final stage of assessment by the regulatory bodies in 2019. Upon approval by the regulatory bodies, the Group plans to ramp up SMP’s production capacity by 10% and mass-produce the new products in 2020. These new products have a strong and stable demand in the medical device market. We also expect that our key clients will take up most of these new products upon manufacturing
We also strive to produce new products with higher product sophistication and higher value added. The Group’s next phase of growth, in its pursuit to become an important global player, will be in the area of various next generation technology products such as electric vehicles and cutting-edge medical devices
From annual report 2019, for financial review 2019 55% of revenue from medical related product. Others from automotive. Prospect for this financial year 2020, the group expect revenue from medical related product (covid-19 related) to increase by 40% while from others to contract by 20% due to MCO, less demand.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
winlast
498 posts
Posted by winlast > 2020-06-03 23:34 | Report Abuse
the banker is flushing out weak holders heavily today in order to acccumulating cheaper price stock for continuing pushing up SCOMNET
price soon